STRIDA项目中涉及全景吡咯戊酮衍生物及MDPV仿制药的中毒病例
该研究为瑞典STRIDA项目的前瞻性病例系列,纳入2011年1月至2016年3月期间因疑似或确认摄入新型精神活性物质(NPS)而至瑞典各医院急诊治疗的患者,收集血液和尿液样本,通过免疫化学和液相色谱-质谱多组分方法分析NPS和其他滥用药物,临床数据来自瑞典毒物信息中心(PIC)咨询和病历记录。共检测到114例涉及11种新型吡咯戊酮药物的中毒,此外17例检测到MDPV,45例检测到α-PVP。最常见检测到的药物为α-PBP、MDPHP和4F-α-PVP。患者年龄16-66岁(中位30岁),84%为男性。尿液和血清浓度高度可变,范围为1 ng/mL至300 µg/mL。多药滥用常见,仅8例(7%)涉及单一吡咯戊酮药物。临床表现包括激越、谵妄、幻觉、过度运动活动、癫痫发作、心动过速、高血压和/或高热。结论认为临床特征符合拟交感中毒综合征,但浓度高度可变,需要分析调查才能获得这些信息。
要点
- 114例经分析确认的11种新型吡咯戊酮衍生物中毒中,仅8例(7%)为单一药物使用,多药滥用常见。
- 最常见检测到的药物为α-PBP、MDPHP和4F-α-PVP,此外17例检测到MDPV,45例检测到α-PVP。
- 患者年龄16-66岁(中位30岁),84%为男性。
- 临床表现包括激越、谵妄、幻觉、过度运动活动、癫痫发作、心动过速、高血压和/或高热,符合拟交感中毒综合征。
- 尿液和血清浓度高度可变,范围为1 ng/mL至300 µg/mL。
适用人群与场景
- 2011年1月至2016年3月期间因疑似或确认摄入NPS而至瑞典各医院急诊治疗的患者。
- 研究纳入经分析确认涉及11种吡咯戊酮药物的中毒病例。
研究设计与关键结果
- 研究类型为病例系列,纳入连续患者;共检测到114例涉及11种新型吡咯戊酮药物的中毒。
- 此外,17例检测到MDPV,45例检测到α-PVP;最常见检测到的药物为α-PBP、MDPHP和4F-α-PVP。
- 患者年龄16-66岁(中位30岁),84%为男性。
- 尿液和血清浓度高度可变,范围为1 ng/mL至300 µg/mL。
- 仅8例(7%)涉及单一吡咯戊酮药物,多药滥用常见,额外物质包括其他NPS和经典精神活性药物。
- 临床表现包括激越、谵妄、幻觉、过度运动活动、癫痫发作、心动过速、高血压和/或高热。
证据类型、等级与局限
- 证据类型:病例系列。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在急诊科遇到疑似NPS中毒患者时,应考虑多种吡咯戊酮衍生物及其他NPS或经典药物混合使用的可能性。
- 临床特征符合拟交感中毒综合征,但尿液和血清浓度高度可变,需依赖分析调查确认物质。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: An increasing number of new psychoactive substances (NPS) of different chemical classes have become available through marketing and sale over the Internet. This report from the Swedish STRIDA project presents the prevalence, laboratory results, and clinical features in intoxications involving 11 stimulant pyrovalerone NPS derivatives over a 5-year period.
STUDY DESIGN: Case series of consecutive patients with admitted or suspected intake of NPS presenting to Swedish hospitals for emergency treatment from January 2011 to March 2016.
PATIENTS AND METHOD: Blood and urine samples were collected from intoxicated patients presenting to hospitals all over Sweden. Analyses of NPS and other drugs of abuse were performed by immunochemical and liquid chromatography-mass spectrometry multi-component methods. Clinical data were collected during consultation with the Swedish Poisons Information Centre (PIC), and retrieved from medical records. The study involved analytically confirmed cases with 11 pyrovalerone drugs.
RESULTS: During the study period, 114 intoxications were detected that involved any of 11 new pyrovalerone drugs. In addition to these new pyrovalerone derivatives, 3,4-methylenedioxypyrovalerone (MDPV) was detected in 17 of the cases and α-pyrrolidinovalerophenone (α-PVP) in 45 cases. Identification was made according to forensic standards and comprised the following substances: 4F-α-PVP, α-PHP, PV8, 4Me-PPP, α-PBP, 4F-PV8, α-PPP, MDPHP, α-PVT, 4Cl-α-PVP, and 4F-α-PHP. The three most frequently detected drugs were α-PBP, MDPHP, and 4F-α-PVP. The age range of patients was 16-66 (median 30) years and 84% were males. The substance concentrations in urine and serum were highly variable, ranging from 1 ng/mL to 300 µg/mL. Poly-drug use was common with only 8 of 114 cases (7%) involving one pyrovalerone drug. The additional substances comprised other NPS and classical psychoactive drugs. The patients showed a variety of clinical signs; agitation, delirium, hallucinations, excessive motor activity, seizures, tachycardia, hypertension, and/or hyperthermia.
CONCLUSIONS: In analytically confirmed NPS-related intoxications, 11 new pyrovalerone derivatives in addition to MDPV and α-PVP were found. The clinical features were consistent with a sympathomimetic toxidrome, but the urine and serum concentrations were highly variable. The results demonstrated that many novel pyrovalerone stimulants were introduced on the recreational NPS drugs market. Analytical investigations were necessary to obtain this information.
参考来源
- Beck O, Bäckberg M, Signell P, et al. Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV copycats. Clin Toxicol (Phila). 2017. PMID: 28895757. doi:10.1080/15563650.2017.1370097
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。